NASDAQ:STIM

Neuronetics Stock Forecast, Price & News

$12.79
+0.32 (+2.57 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.20
Now: $12.79
$12.94
50-Day Range
$11.58
MA: $14.22
$17.80
52-Week Range
$1.70
Now: $12.79
$22.43
Volume308,221 shs
Average Volume503,635 shs
Market Capitalization$324.97 million
P/E RatioN/A
Dividend YieldN/A
Beta3.05
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Neuronetics logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STIM
CUSIPN/A
CIKN/A
Phone(610) 640-4202
Employees126
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.66 million
Book Value$2.57 per share

Profitability

Net Income$-29,040,000.00

Miscellaneous

Market Cap$324.97 million
Next Earnings Date5/4/2021 (Estimated)
OptionableNot Optionable

Headlines

Neuronetics (NASDAQ:STIM) Trading Down 5.1%
March 16, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

469th out of 2,015 stocks

Surgical & Medical Instruments Industry

40th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$12.79
+0.32 (+2.57 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neuronetics (NASDAQ:STIM) Frequently Asked Questions

Is Neuronetics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neuronetics stock.
View analyst ratings for Neuronetics
or view top-rated stocks.

What stocks does MarketBeat like better than Neuronetics?

Wall Street analysts have given Neuronetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neuronetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Neuronetics?

Neuronetics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 473,400 shares, a drop of 23.7% from the February 28th total of 620,800 shares. Based on an average trading volume of 494,300 shares, the days-to-cover ratio is presently 1.0 days.
View Neuronetics' Short Interest
.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Neuronetics
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) posted its earnings results on Monday, March, 1st. The company reported ($0.19) EPS for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.05. The business had revenue of $15.58 million for the quarter, compared to the consensus estimate of $15.21 million. Neuronetics had a negative net margin of 61.44% and a negative trailing twelve-month return on equity of 88.76%.
View Neuronetics' earnings history
.

How has Neuronetics' stock been impacted by Coronavirus (COVID-19)?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STIM stock has increased by 517.9% and is now trading at $12.79.
View which stocks have been most impacted by COVID-19
.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its FY 2021 Pre-Market earnings guidance on Tuesday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $58-62 million, compared to the consensus revenue estimate of $62.58 million.

What price target have analysts set for STIM?

5 brokerages have issued 1 year price targets for Neuronetics' shares. Their forecasts range from $8.00 to $25.00. On average, they expect Neuronetics' share price to reach $19.25 in the next year. This suggests a possible upside of 50.5% from the stock's current price.
View analysts' price targets for Neuronetics
or view top-rated stocks among Wall Street analysts.

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Stephen J. Furlong M.S., Sr. VP, CFO & Treasurer (Age 56, Pay $536.71k)
  • Mr. Keith J. Sullivan, Pres, CEO & Director (Age 63)
  • Mr. W. Andrew Macan, Sr. VP, Gen. Counsel, Chief Compliance Officer, Sec. & Member of Office of the Pres (Age 48)
  • Ms. Janie Bates, VP of Marketing
  • Ms. Sara Grubbs, VP of Sales
  • Ms. Kara Thornton, VP of HR & Sr. Director

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $12.79.

How much money does Neuronetics make?

Neuronetics has a market capitalization of $324.97 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

How many employees does Neuronetics have?

Neuronetics employs 126 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is www.neurostar.com.

Where are Neuronetics' headquarters?

Neuronetics is headquartered at 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at (610) 640-4202 or via email at [email protected]


This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.